NCT00597129View on ClinicalTrials.gov

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

90Y-hPAM4

Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

46526

Goshen Cancer Center, Goshen

68198

Nebraska Medical Center, Omaha

07101

University of Medicine and Dentistry, Newark

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY